TriangleStudy reference · NCT03470922
RELATIVITY-047
Nivolumab plus relatlimab: three-year survival update
Fixed release · explorer-2026-09-11At three years, estimated overall survival was 54.6% with nivolumab plus relatlimab and 48% with nivolumab. This update was exploratory.
Estimated survival at 3 years
Overall survival · percentage alive in each trial group
The small black line shows uncertainty (95% confidence interval), where available. These estimates describe study groups, not an individual’s chance of survival.
Exploratory overall-survival hazard ratio: 0.80 (95% CI 0.66–0.99), combination versus nivolumab.
Grade 3–4 treatment-related adverse events
Three-year update; events collected through at least 100 days after discontinuation. Lower percentages mean fewer reported severe events.
355 combination; 359 nivolumab participants.
Put the research in context
Who was studied?
Compare the reported population with what you know. It is fine to be unsure—those are useful questions for your care team.
Read the original sources →These are reported population details, not a complete list of eligibility criteria. Who could enroll, who participated, and whose results were analyzed can differ. This checklist does not score your match, recommend treatment, or determine trial eligibility.
Your selections and question stay on this page only. They are not saved or sent to Triangle. Copy your note before leaving; refreshing clears it.
Keep your next appointment in mind.
Copy your question, then sign in to Triangle.
This note is not transferred automatically.
Study design & endpoints
Double-blind, randomized phase 2/3 trial; 714 participants.
Primary: progression-free survival by blinded central review. Overall survival was secondary. This three-year update is exploratory and descriptive.
What the chart cannot tell you
- All efficacy analyses in this update were exploratory and descriptive. A confidence interval excluding 1 does not make this a new confirmatory OS result.
- The results do not compare this combination with nivolumab plus ipilimumab.
- Quality-of-life results are not included in this preview.
Results are group estimates, not a personalized forecast, treatment recommendation, or confirmation of trial eligibility.
Full results table
| Group | Efficacy n | Median overall survival, months (CI) | Survival at 3 years (95% CI) | Severe events |
|---|---|---|---|---|
| Nivolumab + relatlimab | 355 | 51 (34.0–not reached) | 54.6% (49.2–59.6%) | 22% |
| Nivolumab | 359 | 34.1 (25.2–44.7) | 48% (42.7–53.1%) | 12% |
Grade 3–4 treatment-related adverse events. 355 combination; 359 nivolumab participants.
Median survival is a time point, not average lifespan. Confidence levels and analysis details are reported with the source.